Abstract
Raltegravir, a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has pH-dependent solubility. Raltegravir plasma concentration increases with omeprazole coadministration in healthy subjects; this is likely secondary to an increase in bioavailability attributable to increased gastric pH. Increased gastric pH has been reported in HIV-1-infected individuals, and the effects of omeprazole in this intended population may be diminished. Further investigation is necessary.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Anti-HIV Agents / pharmacokinetics*
-
Anti-HIV Agents / therapeutic use
-
Drug Interactions*
-
Female
-
HIV Infections / drug therapy
-
Humans
-
Male
-
Middle Aged
-
Omeprazole / pharmacokinetics*
-
Omeprazole / therapeutic use
-
Plasma / chemistry*
-
Pyrrolidinones / pharmacokinetics*
-
Pyrrolidinones / therapeutic use
-
Raltegravir Potassium
-
Young Adult
Substances
-
Anti-HIV Agents
-
Pyrrolidinones
-
Raltegravir Potassium
-
Omeprazole